FDA approval: Fexofenadine Hydrochloride

AI Summary

The FDA approved fexofenadine hydrochloride tablets (60 mg and 180 mg oral formulations) via abbreviated new drug application ANDA220413 on 30 July 2026, sponsored by Dr Reddy's. This record confirms regulatory authorization but does not contain clinical trial data, efficacy endpoints, or comparative safety information.

Plain-language summary

FDA approval of a generic fexofenadine hydrochloride formulation; establishes regulatory authorization but does not report clinical trial efficacy or comparative outcomes.

Study design

As stated by the source record.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This approval establishes that the fexofenadine hydrochloride formulation meets FDA standards for bioavailability and manufacturing quality as a generic product. Clinicians may use this formulation as an alternative to branded antihistamines, but should refer to established clinical evidence for fexofenadine efficacy and safety, which is not reported in this regulatory record.

Caveats

• This record does not contain clinical trial results, efficacy data, or safety outcomes.
• No comparative bioavailability data, pharmacokinetics, or clinical endpoint data are reported.
• The approval status does not indicate the basis of approval (e.g., whether bioequivalence or full clinical trials were required).
• No information on adverse events, contraindications, or population-specific safety is provided in this record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.